颅内病灶高剂量再程放疗的疗效与安全性及基于累积EQD2剂量的剂量学分析
该回顾性研究分析76例2013年2月至2016年9月接受重复颅内放疗患者(34例原发脑肿瘤复发,42例脑转移),基于刚性配准累积EQD2剂量分布进行剂量学分析并随访毒性、局部控制与总生存。结果显示重复放疗安全有效,中位累积处方EQD2为96.5 Gy2,74%患者仅低级别急性毒性,仅2例>G3毒性;原发脑肿瘤局部失败中位时间未达到,脑转移为24周。
要点
- 重复颅内放疗中位累积处方EQD2为96.5 Gy2,74%患者仅低级别急性毒性。
- 仅2例记录到>G3毒性,支持在脑剂量≤120 Gy2 EQD2下重复放疗安全。
- 原发脑肿瘤局部失败中位时间未达到,脑转移为24周。
核心结论
- 对复发原发或继发脑肿瘤患者,重复放疗在脑剂量达120 Gy2 EQD2、脑干剂量低于100 Gy2、视交叉和视神经剂量低于75 Gy2 EQD2时安全有效。
研究设计与样本
- 回顾性分析2013年2月至2016年9月76例接受重复颅内放疗患者,34例原发脑肿瘤复发、42例脑转移。
- 基于刚性图像配准累积EQD2剂量分布进行剂量学分析,随访收集毒性、局部控制和总生存数据。
主要发现
- 全部放疗疗程中位累积处方EQD2为96.5 Gy2。
- 接受超过100 Gy2患者脑D(0.1 cc)中位为114 Gy2,最高剂量161.5 Gy2。
- 74%患者发生低级别(G1-G2)急性毒性,仅2例记录到高级别(>G3)毒性。
- 自首次再程放疗起中位总生存为57周(范围4-186周)。
- 原发脑肿瘤患者局部失败中位时间未达到,脑转移患者为24周(范围1-77周)。
关键数值与推荐
- 脑剂量可达120 Gy2 EQD2。
- 脑干剂量低于100 Gy2。
- 视交叉和视神经剂量低于75 Gy2 EQD2。
临床怎么用
- 对复发原发或继发脑肿瘤可考虑重复放疗,但需通过EQD2累积剂量评估确保脑、脑干、视交叉和视神经剂量不超过上述限值。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: The use of cranial re-irradiation is growing with improving overall survival and the advent of high-precision radiotherapy techniques. Still the value of re-irradiation needs careful evaluation regarding safety and efficacy. We analyzed dosimetric and clinical data of patients receiving cranial re-irradiation using EQD2 sum plans. METHODS AND MATERIAL: We retrospectively analyzed the data of 76 patients who received repeated cranial radiotherapy from 02/2013 to 09/2016. 34 patients suffered from recurrent primary brain tumors, 42 from brain metastases. Dosimetric analysis was performed accumulating EQD2 dose distributions based on rigid image registration. Clinical and radiological data was collected at follow-ups including toxicity, local control and overall survival. RESULTS: In total 76 patients had at least 2 courses of intracranial radiotherapy. The median accumulated prescription EQD2 dose was 96.5 Gy2 for all radiation courses combined. The median D(0.1 cc) of the brain for patients receiving more than 100 Gy2 was 114 Gy2 with a highest dose of 161.5 Gy2. 74% of patients suffered from low grade (G1-G2) acute toxicity, only two high grade (>G3) toxicities were recorded.Median overall survival from the time of first re-irradiation was 57 weeks (range 4-186 weeks). The median time to local failure for patients with a primary brain tumor was not reached and 24 weeks (range 1-77 weeks) for patients with brain metastases. CONCLUSION: Repeated radiotherapy appears both safe and efficient in patients with recurrent primary or secondary brain tumors with doses to the brain up to 120 Gy2 EQD2, doses below 100 Gy2 for brainstem and doses below 75 Gy2 EQD2 to chiasm and optic nerves.
引用
- Stiefel I, Schröder C, Tanadini-Lang S, et al. High-dose re-irradiation of intracranial lesions - Efficacy and safety including dosimetric analysis based on accumulated EQD2Gy dose EQD calculation. Clin Transl Radiat Oncol. 2021. PMID: 33659717. doi:10.1016/j.ctro.2021.01.011
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。